Healthcare (XLV) vs Consumer Staples (XLP)
XLV (Health Care Select Sector SPDR Fund) tracks healthcare with top weights Eli Lilly ~15 percent, UnitedHealth ~9 percent, J&J ~6 percent, Merck ~5 percent, AbbVie ~5 percent, Novo Nordisk ADR (limited US exposure). XLP (Consumer Staples Select Sector SPDR Fund) tracks consumer staples.
Also known as: Healthcare (XLV) (ETF_XLV, healthcare) · Consumer Staples (XLP) (ETF_XLP, consumer staples)
Why This Comparison Matters
XLV (Health Care Select Sector SPDR Fund) tracks healthcare with top weights Eli Lilly ~15 percent, UnitedHealth ~9 percent, J&J ~6 percent, Merck ~5 percent, AbbVie ~5 percent, Novo Nordisk ADR (limited US exposure). XLP (Consumer Staples Select Sector SPDR Fund) tracks consumer staples. April 2026: XLV ~$160; XLP ~$80. Both defensive sectors. XLV leveraged to GLP-1 drug cycle (Eli Lilly Mounjaro/Zepbound, Novo Nordisk Ozempic/Wegovy). XLP pressured by GLP-1 (Mounjaro/Ozempic reducing food/beverage demand affecting MCD/SBUX/PEP/KO). The same drug cycle helps XLV and hurts XLP - clean opposing exposures.
The April 2026 Configuration
XLV ~$160; XLP ~$80. XLV/XLP ratio approximately 2.0.
XLV composition: Eli Lilly (LLY) ~15% (GLP-1 dominant); UnitedHealth (UNH) ~9% (managed care); Johnson & Johnson (JNJ) ~6% (pharma); Merck (MRK) ~5% (pharma + Keytruda); AbbVie (ABBV) ~5% (pharma); Pfizer (PFE) ~3%; Bristol-Myers (BMY) ~3%; Thermo Fisher (TMO) ~3%; Abbott (ABT) ~3%; Danaher (DHR) ~2%; Cigna ~2%; Humana ~1%; Medtronic ~1%; CVS Health ~1%.
XLP composition: Procter & Gamble ~14%; Costco ~12%; Coca-Cola ~9%; Walmart ~9%; PepsiCo ~6%.
April 2026: XLV outperforming XLP modestly. Eli Lilly +30% past 12 months on GLP-1 + obesity drug pipeline. UnitedHealth stable. Pharma/biotech selective. XLP pressured by GLP-1 affecting food/beverage; Costco + Walmart strength offsetting.
GLP-1 Driving the Divergence
GLP-1 weight-loss drugs (Ozempic, Wegovy from Novo Nordisk; Mounjaro, Zepbound from Eli Lilly) creating clean opposing sector exposure.
XLV beneficiaries. Eli Lilly: LLY stock +30% past 12 months. Mounjaro/Zepbound revenue ramp. Lilly market cap surged to $700B+ (largest healthcare). Novo Nordisk also benefits but ADR limited weight in XLV.
XLP victims. Coca-Cola, PepsiCo, McDonald's, Starbucks, Mondelez face volume headwinds as GLP-1 users consume less food/beverage. Estimated 5-15% volume reduction in some categories. PEP/KO/MDLZ/MCD pricing power offsets some impact but margins compressed.
The practical implication: GLP-1 cycle specifically widens XLV/XLP ratio. Both sectors traditionally defensive but GLP-1 mechanism creates direct transfer of consumer spending from food/beverage (XLP) to drugs (XLV).
Beyond GLP-1: Other XLV Drivers
XLV has multiple growth drivers beyond GLP-1.
Biotech innovation: Keytruda (Merck), Humira biosimilars, gene therapy, oncology pipeline.
Managed care: UnitedHealth (UNH), Humana (HUM), CVS Health/Aetna. Medicare Advantage growth.
Medical devices: Abbott, Medtronic, Boston Scientific, Stryker. Aging demographics.
Life sciences: Thermo Fisher, Danaher. Research/biotech tools.
Conditional Forward Response (Tail Events)
How Consumer Staples (XLP) has historically behaved in the 5 sessions following a top-decile or bottom-decile daily move in Healthcare (XLV). Computed from 1,285 aligned daily observations ending .
Following these triggers, Consumer Staples (XLP) rises 0.18% on average over the next 5 sessions, versus an unconditional baseline of +0.09%. 128 qualifying events; Consumer Staples (XLP) closed positive in 52% of them.
90-Day Statistics
Explore Each Metric
Related Scenarios & Forecasts
Get daily macro analysis comparing key metrics delivered to your inbox. Stay ahead of market-moving divergences.
Frequently Asked Questions
What are XLV and XLP?+
XLV (Health Care Select Sector SPDR Fund) tracks healthcare with top weights Eli Lilly (LLY) ~15% (GLP-1 dominant), UnitedHealth (UNH) ~9% (managed care), Johnson & Johnson ~6%, Merck ~5%, AbbVie ~5%, Pfizer ~3%, Bristol-Myers ~3%, Thermo Fisher ~3%, Abbott ~3%. XLP (Consumer Staples Select Sector SPDR Fund) tracks consumer staples with top weights P&G ~14%, Costco ~12%, KO ~9%, WMT ~9%, PEP ~6%. April 2026: XLV ~$160; XLP ~$80. XLV/XLP ratio ~2.0. Both defensive sectors. XLV leveraged to GLP-1 drug cycle. XLP pressured by GLP-1 (food/beverage volume headwinds).
How does GLP-1 drive the divergence?+
GLP-1 weight-loss drugs (Ozempic, Wegovy from Novo Nordisk; Mounjaro, Zepbound from Eli Lilly) creating clean opposing sector exposure. XLV beneficiaries: Eli Lilly +30% past 12 months. Mounjaro/Zepbound revenue ramp. Lilly market cap surged to $700B+ (largest healthcare). XLP victims: Coca-Cola, PepsiCo, McDonald's, Starbucks, Mondelez face volume headwinds as GLP-1 users consume less food/beverage. Estimated 5-15% volume reduction in some categories. PEP/KO/MDLZ/MCD pricing power offsets but margins compressed. GLP-1 cycle specifically widens XLV/XLP ratio. Direct transfer of consumer spending from food/beverage (XLP) to drugs (XLV).
What other XLV drivers beyond GLP-1?+
Multiple growth drivers. Biotech innovation: Keytruda (Merck), Humira biosimilars, gene therapy, oncology pipeline. Managed care: UnitedHealth, Humana, CVS Health/Aetna. Medicare Advantage growth. Medical devices: Abbott, Medtronic, Boston Scientific, Stryker. Aging demographics. Life sciences: Thermo Fisher, Danaher. Research/biotech tools. April 2026: XLV diverse exposure. UnitedHealth stable. JNJ split (Kenvue separated). Merck Keytruda dominant in immuno-oncology. AbbVie post-Humira transition. XLV/XLP captures GLP-1 transfer + defensive bid. XLV broader healthcare innovation provides additional growth tailwind beyond just GLP-1.
Related Comparisons
Explore Across Convex
Data sourced from FRED, CoinGecko, CBOE, and other providers. This page is for informational purposes only and does not constitute financial advice. Past performance does not guarantee future results.